Notable Labs (NASDAQ:NTBL) Given New $7.00 Price Target at Chardan Capital

Notable Labs (NASDAQ:NTBL) had its price objective decreased by Chardan Capital from $9.00 to $7.00 in a research note issued to investors on Monday, Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Separately, JMP Securities decreased their target price on Notable Labs from $13.00 to $9.00 and set a market outperform rating for the company in a research note on Tuesday, December 19th.

Notable Labs Price Performance

NASDAQ NTBL opened at $0.97 on Monday. The business’s 50 day simple moving average is $1.43. Notable Labs has a one year low of $0.83 and a one year high of $11.20. The firm has a market capitalization of $2.15 million, a PE ratio of -0.27 and a beta of 0.77. The company has a quick ratio of 5.65, a current ratio of 5.65 and a debt-to-equity ratio of 0.02.

Institutional Investors Weigh In On Notable Labs

An institutional investor recently bought a new position in Notable Labs stock. Industry Ventures L.L.C. purchased a new position in Notable Labs, Ltd. (NASDAQ:NTBL) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 204,424 shares of the company’s stock, valued at approximately $386,000. Notable Labs makes up approximately 0.6% of Industry Ventures L.L.C.’s portfolio, making the stock its 6th largest position. Industry Ventures L.L.C. owned 9.21% of Notable Labs as of its most recent SEC filing. Institutional investors own 70.48% of the company’s stock.

Notable Labs Company Profile

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic.